A SERIES OF PT(LL) COMPLEXES WITH ANTITUMOR PROPERTIES: [1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]PtL(2) (meso-1-PtL(2)) and [erythro-1-(2,6-dichloro-4-hydroxyphenyl)-2-(2-halo-4-hydroxyphenyl)ethylenediamine]PtL(2), [2L=2Cl-,2I-,SO(4) (2)-; halo = F (erythro-8-PtL(2)),halo = Cl (erythro-9-PtL(2))] has been modelled by molecular mechanics (MM). The MM calculations were carried out for different isomers and ligand conformations meso-delta, meso-lambda, d,l-delta, d,I-lambda. The compounds with the lowest MM energies have the same geometries as those obtained by X-ray analysis. The calculated MMX energy orders: meso-1-PtL(2) < erythro-9-PtL(2) < erythro-8-PtL(2) for L=I-, Cl- and SO(4) (2-) are reverse to the known antitumor activity order - the lowest energy complex (the most stable one)is the one with the highest estrogen activity (meso-1-PtL(2)). The type of the leaving group (L) does not alter the energy order, which is in agreement with the biological experiments that show a slight dependence of the estrogen properties on the leaving group type.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2365099PMC
http://dx.doi.org/10.1155/MBD.1998.91DOI Listing

Publication Analysis

Top Keywords

antitumor activity
8
molecular mechanics
8
leaving group
8
platinum compounds
4
compounds antitumor
4
activity studied
4
studied molecular
4
mechanics series
4
series ptll
4
ptll complexes
4

Similar Publications

Ebastine-mediated destabilization of E3 ligase MKRN1 protects against metabolic dysfunction-associated steatohepatitis.

Cell Mol Life Sci

January 2025

Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, 03722, Republic of Korea.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic condition encompassing metabolic dysfunction-associated steatotic liver (MASL) and metabolic dysfunction-associated steatohepatitis (MASH), which can progress to fibrosis, cirrhosis, or hepatocellular carcinoma (HCC). The heterogeneous and complex nature of MASLD complicates optimal drug development. Ebastine, an antihistamine, exhibits antitumor activity in various types of cancer.

View Article and Find Full Text PDF

The novel piperine derivative MHJ-LN inhibits breast cancer by inducing apoptosis via p53 activation.

Naunyn Schmiedebergs Arch Pharmacol

January 2025

Key Laboratory of Marine Pharmaceutical Compound Screening, College of Pharmacy, Jiangsu Ocean University, Lianyungang, China.

Triple-negative breast cancer (TNBC) is characterized by high aggressiveness and recurrence rates due to the lack of effective treatment options. Piperine, a natural alkaloid extracted from black pepper, has demonstrated significant anticancer potential in recent years. Therefore, developing piperine derivatives to enhance its anticancer effects holds critical clinical significance.

View Article and Find Full Text PDF

Cyclin-dependent kinase 9 (CDK9) is considered as an important target in the research of antitumor drugs. Taking the CDK2/9 inhibitor CYC065 as the positive control and an in-house library compound (64) as the lead compound, four classes of 22 target compounds with 9H purine as the core structure were designed to establish structure-activity relationships (SAR). In general, SAR of 9H purine CDK9 inhibitors is systematically described in this paper, resulting in the discovery of two compounds (B2 and B5) with further research value.

View Article and Find Full Text PDF

7-Aminoactinomycin D (7AAMD) is the fluorescent analogue of the anticancer drug actinomycin D (AMD). In order to overcome toxic side effects and enhanced bioavailability of 7AAMD, micellar drug carrier systems could be useful. We have used cationic (hexadecetyltrimethylammonium bromide [CTAB]), anionic (sodium dodecyl sulphate [SDS]) and non-ionic (t-octylphenoxypolyoxyethanol, Triton-X100 [TX 100]) surfactants to prepare micelle.

View Article and Find Full Text PDF

Lysosome-targeting chimeras (LYTACs) have recently emerged as a promising therapeutic strategy for degrading extracellular and membrane-associated pathogenic proteins by hijacking lysosome-targeting receptors. However, the antitumor performance of LYTAC is limited by its insufficient tumor accumulation and nonspecific activation. Additionally, the synergistic effects of LYTACs and other therapeutic modalities are crucial.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!